Last reviewed · How we verify
Probiotic Vivomixx
Probiotic Vivomixx is a Probiotic Small molecule drug developed by University of Milan. It is currently FDA-approved for Irritable bowel syndrome, Inflammatory bowel disease support, Antibiotic-associated diarrhea.
Vivomixx is a multi-strain probiotic formulation that restores beneficial gut microbiota to improve intestinal barrier function and modulate immune responses.
Vivomixx is a multi-strain probiotic formulation that restores beneficial gut microbiota to improve intestinal barrier function and modulate immune responses. Used for Irritable bowel syndrome, Inflammatory bowel disease support, Antibiotic-associated diarrhea.
At a glance
| Generic name | Probiotic Vivomixx |
|---|---|
| Sponsor | University of Milan |
| Drug class | Probiotic |
| Modality | Small molecule |
| Therapeutic area | Gastroenterology |
| Phase | FDA-approved |
Mechanism of action
The product contains eight freeze-dried bacterial strains (including Streptococcus thermophilus, Bifidobacterium, and Lactobacillus species) that colonize the intestinal tract. These strains produce short-chain fatty acids, enhance tight junction integrity, and promote anti-inflammatory immune responses, thereby supporting gastrointestinal health and potentially reducing symptoms associated with dysbiosis.
Approved indications
- Irritable bowel syndrome
- Inflammatory bowel disease support
- Antibiotic-associated diarrhea
- General gastrointestinal health maintenance
Common side effects
- Bloating
- Flatulence
- Abdominal discomfort
- Mild gastrointestinal symptoms
Key clinical trials
- Acceptability and Adherence to Different Dosing Regimens of the Multistrain Probiotic Vivomixx® 460 Neo 9 in Adults Receiving Antibiotic Therapy. (NA)
- Maternal Probiotic Intervention to Improve Gut Health (PHASE2)
- Probiotic For the Improvement of Environmental Enteropathy in Pregnant Women in Senegal (PHASE2)
- Intervention on New Onset-T1D Children (NA)
- Effects of a Multi-strain Oral Probiotic on the Vaginal Microbiota Composition in Healthy Women and Women with Endometriosis (NA)
- Effects of a Probiotic in Hypertension (NA)
- Preventive Effect of Perinatal Oral Probiotic Supplementation (POPS) on Neonatal Jaundice (PHASE2)
- Impact of Probiotics in HIV-positive Patients With Neurocognitive Disorders (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Probiotic Vivomixx CI brief — competitive landscape report
- Probiotic Vivomixx updates RSS · CI watch RSS
- University of Milan portfolio CI
Frequently asked questions about Probiotic Vivomixx
What is Probiotic Vivomixx?
How does Probiotic Vivomixx work?
What is Probiotic Vivomixx used for?
Who makes Probiotic Vivomixx?
What drug class is Probiotic Vivomixx in?
What development phase is Probiotic Vivomixx in?
What are the side effects of Probiotic Vivomixx?
Related
- Drug class: All Probiotic drugs
- Manufacturer: University of Milan — full pipeline
- Therapeutic area: All drugs in Gastroenterology
- Indication: Drugs for Irritable bowel syndrome
- Indication: Drugs for Inflammatory bowel disease support
- Indication: Drugs for Antibiotic-associated diarrhea
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing